Spago Nanomedical AB

Spago Nanomedical is a Swedish biotechnology company developing products for precision imaging and radionuclide treatment of cancer and other devastating diseases. The company´s two main development programs, SpagoPix and Tumorad, are based on a unique and proprietary platform for physiological accumulation of optimized and functionalized polymeric particles in tumors. Candidate drug SN132D is a gadolinium-free contrast agent for precision magnetic resonance imaging (MRI) with exceptionally high signal strength. By selective physiological accumulation in tumor tissue, SpagoPix meets a well recognized need for significantly improved soft tissue tumor imaging with further potential in inflammatory endometriosis. Candidate drug 177Lu-SN201 is a novel radiopharmaceutical nanoprticle with potential to expand the scope of radionuclide therapy in solid tumor indications not currently targetable by other modalities, as monotherapy or in combinations with established treatments.